vs

Side-by-side financial comparison of CVB FINANCIAL CORP (CVBF) and Organogenesis Holdings Inc. (ORGO). Click either name above to swap in a different company.

Organogenesis Holdings Inc. is the larger business by last-quarter revenue ($225.6M vs $133.8M, roughly 1.7× CVB FINANCIAL CORP). On growth, Organogenesis Holdings Inc. posted the faster year-over-year revenue change (78.1% vs 8.4%). CVB FINANCIAL CORP produced more free cash flow last quarter ($217.3M vs $34.8M). Over the past eight quarters, Organogenesis Holdings Inc.'s revenue compounded faster (43.2% CAGR vs 2.8%).

CVB Financial Corp is a U.S. bank holding company operating Citizens Business Bank, serving mainly California markets. It offers commercial banking, personal banking and wealth management solutions for small to medium enterprises, professional firms and individual consumers, with core services including loans, deposit accounts and asset management.

Organogenesis Holdings Inc. is a leading regenerative medicine firm specializing in developing and manufacturing advanced therapeutic products for wound care, surgical repair, sports medicine, and dermatology. It serves healthcare providers and patients primarily in the U.S. and select international markets, offering clinically validated solutions for unmet medical needs.

CVBF vs ORGO — Head-to-Head

Bigger by revenue
ORGO
ORGO
1.7× larger
ORGO
$225.6M
$133.8M
CVBF
Growing faster (revenue YoY)
ORGO
ORGO
+69.8% gap
ORGO
78.1%
8.4%
CVBF
More free cash flow
CVBF
CVBF
$182.6M more FCF
CVBF
$217.3M
$34.8M
ORGO
Faster 2-yr revenue CAGR
ORGO
ORGO
Annualised
ORGO
43.2%
2.8%
CVBF

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
CVBF
CVBF
ORGO
ORGO
Revenue
$133.8M
$225.6M
Net Profit
$43.7M
Gross Margin
Operating Margin
55.6%
28.1%
Net Margin
19.4%
Revenue YoY
8.4%
78.1%
Net Profit YoY
469.5%
EPS (diluted)
$0.41
$0.31

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CVBF
CVBF
ORGO
ORGO
Q4 25
$133.8M
$225.6M
Q3 25
$128.6M
$150.9M
Q2 25
$126.4M
$101.0M
Q1 25
$126.7M
$86.7M
Q4 24
$123.5M
$126.7M
Q3 24
$126.5M
$115.2M
Q2 24
$125.3M
$130.2M
Q1 24
$126.6M
$110.0M
Net Profit
CVBF
CVBF
ORGO
ORGO
Q4 25
$43.7M
Q3 25
$52.6M
$21.6M
Q2 25
$50.6M
$-9.4M
Q1 25
$51.1M
$-18.8M
Q4 24
$7.7M
Q3 24
$51.2M
$12.3M
Q2 24
$50.0M
$-17.0M
Q1 24
$48.6M
$-2.1M
Gross Margin
CVBF
CVBF
ORGO
ORGO
Q4 25
Q3 25
Q2 25
Q1 25
72.6%
Q4 24
75.5%
Q3 24
76.7%
Q2 24
77.6%
Q1 24
73.9%
Operating Margin
CVBF
CVBF
ORGO
ORGO
Q4 25
55.6%
28.1%
Q3 25
53.7%
13.7%
Q2 25
54.4%
-12.5%
Q1 25
54.9%
-30.9%
Q4 24
55.1%
8.1%
Q3 24
53.5%
5.4%
Q2 24
54.9%
-10.7%
Q1 24
52.8%
-3.5%
Net Margin
CVBF
CVBF
ORGO
ORGO
Q4 25
19.4%
Q3 25
40.9%
14.3%
Q2 25
40.0%
-9.3%
Q1 25
40.3%
-21.7%
Q4 24
6.1%
Q3 24
40.5%
10.7%
Q2 24
39.9%
-13.1%
Q1 24
38.4%
-1.9%
EPS (diluted)
CVBF
CVBF
ORGO
ORGO
Q4 25
$0.41
$0.31
Q3 25
$0.38
$0.11
Q2 25
$0.37
$-0.10
Q1 25
$0.36
$-0.17
Q4 24
$0.36
$0.05
Q3 24
$0.37
$0.09
Q2 24
$0.36
$-0.13
Q1 24
$0.35
$-0.02

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CVBF
CVBF
ORGO
ORGO
Cash + ST InvestmentsLiquidity on hand
$376.4M
$93.7M
Total DebtLower is stronger
Stockholders' EquityBook value
$2.3B
$300.1M
Total Assets
$15.6B
$598.7M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CVBF
CVBF
ORGO
ORGO
Q4 25
$376.4M
$93.7M
Q3 25
$783.9M
$63.7M
Q2 25
$738.6M
$73.1M
Q1 25
$529.1M
$110.0M
Q4 24
$204.7M
$135.6M
Q3 24
$453.5M
$94.3M
Q2 24
$844.2M
$89.9M
Q1 24
$949.6M
$88.6M
Total Debt
CVBF
CVBF
ORGO
ORGO
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
$62.3M
Q2 24
$63.8M
Q1 24
$65.2M
Stockholders' Equity
CVBF
CVBF
ORGO
ORGO
Q4 25
$2.3B
$300.1M
Q3 25
$2.3B
$255.1M
Q2 25
$2.2B
$233.2M
Q1 25
$2.2B
$242.9M
Q4 24
$2.2B
$262.9M
Q3 24
$2.2B
$278.5M
Q2 24
$2.1B
$263.5M
Q1 24
$2.1B
$278.0M
Total Assets
CVBF
CVBF
ORGO
ORGO
Q4 25
$15.6B
$598.7M
Q3 25
$15.7B
$509.8M
Q2 25
$15.4B
$461.1M
Q1 25
$15.3B
$467.4M
Q4 24
$15.2B
$497.9M
Q3 24
$15.4B
$446.3M
Q2 24
$16.2B
$443.2M
Q1 24
$16.5B
$458.5M
Debt / Equity
CVBF
CVBF
ORGO
ORGO
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
0.22×
Q2 24
0.24×
Q1 24
0.23×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CVBF
CVBF
ORGO
ORGO
Operating Cash FlowLast quarter
$221.4M
$39.4M
Free Cash FlowOCF − Capex
$217.3M
$34.8M
FCF MarginFCF / Revenue
162.4%
15.4%
Capex IntensityCapex / Revenue
3.0%
2.1%
Cash ConversionOCF / Net Profit
0.90×
TTM Free Cash FlowTrailing 4 quarters
$391.5M
$-24.5M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CVBF
CVBF
ORGO
ORGO
Q4 25
$221.4M
$39.4M
Q3 25
$81.5M
$3.1M
Q2 25
$53.1M
$-32.9M
Q1 25
$41.9M
$-19.9M
Q4 24
$249.8M
$10.9M
Q3 24
$71.4M
$8.7M
Q2 24
$26.1M
$4.7M
Q1 24
$77.5M
$-10.2M
Free Cash Flow
CVBF
CVBF
ORGO
ORGO
Q4 25
$217.3M
$34.8M
Q3 25
$80.7M
$844.0K
Q2 25
$52.3M
$-36.5M
Q1 25
$41.2M
$-23.6M
Q4 24
$244.6M
$7.6M
Q3 24
$70.2M
$6.1M
Q2 24
$24.4M
$2.9M
Q1 24
$77.3M
$-12.4M
FCF Margin
CVBF
CVBF
ORGO
ORGO
Q4 25
162.4%
15.4%
Q3 25
62.8%
0.6%
Q2 25
41.4%
-36.1%
Q1 25
32.5%
-27.2%
Q4 24
198.0%
6.0%
Q3 24
55.5%
5.3%
Q2 24
19.5%
2.2%
Q1 24
61.1%
-11.3%
Capex Intensity
CVBF
CVBF
ORGO
ORGO
Q4 25
3.0%
2.1%
Q3 25
0.7%
1.5%
Q2 25
0.7%
3.6%
Q1 25
0.5%
4.2%
Q4 24
4.2%
2.7%
Q3 24
1.0%
2.2%
Q2 24
1.4%
1.4%
Q1 24
0.1%
2.0%
Cash Conversion
CVBF
CVBF
ORGO
ORGO
Q4 25
0.90×
Q3 25
1.55×
0.14×
Q2 25
1.05×
Q1 25
0.82×
Q4 24
1.43×
Q3 24
1.39×
0.71×
Q2 24
0.52×
Q1 24
1.59×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons